Budget Impact Analysis of Rozanolixizumab for the Treatment of Generalized Myasthenia Gravis (gMG) in Greece
Author(s)
CHRISTINA GOLNA, LLM, MSc1, Pavlos Golnas, MSc1, Michael Feretos, MSc2, Sergei Kalynych, PhD3, Ramona SCHMID, MSc, PharmD4, Hicham Benhaddi, MSc4, Vasilios K. Kimiskidis, MD, PhD5, Kyriakos Souliotis, PhD6.
1Health Policy Institute, Maroussi, Greece, 2UCB, Athens, Greece, 3UCB, Prague, Czech Republic, 4UCB, Colombes, France, 5Department of Neurology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, 6School of Social and Political Sciences, University of Peloponnese, Corinth, Greece.
1Health Policy Institute, Maroussi, Greece, 2UCB, Athens, Greece, 3UCB, Prague, Czech Republic, 4UCB, Colombes, France, 5Department of Neurology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, 6School of Social and Political Sciences, University of Peloponnese, Corinth, Greece.
OBJECTIVES: To assess the budget impact of reimbursing rozanolixizumab as a treatment for adult patients with moderate-to-severe generalized myasthenia gravis (gMG) in Greece from the perspective of the third-party payer, namely the National Organization for Health Services Provision (EOPYY).
METHODS: A budget impact model (BIM) was developed over a five-year time horizon (2025-2029) to estimate the cost of treating eligible gMG patients with existing therapies, including eculizumab, efgartigimod, ravulizumab, rituximab, intravenous immunoglobulin, or rozanolixizumab. Standard of care treatment is added to all comparators in clinical practice in Greece and was not accounted for in the BIM. The analysis incorporated epidemiological data on gMG prevalence and treatment uptake estimates. Patients received rozanolixizumab instead of eculizumab, efgartigomod, ravulizumab or rituximab. Rozanolixizumab had a mean annualized rate of 3.4 cycles and 17.8 infusions. Cost inputs included drug acquisition, administration, disease management and adverse event costs, sourced from market research, published literature and clinical expert input. Costs were presented in 2024 Euros.
RESULTS: Reimbursing rozanolixizumab for 2.9%, 3.1%, 3.7%, 4.5% and 5.2% of total eligible gMG patients in years 1 to 5 respectively would lead to a cumulative €10.9 million saving on the budget of EOPYY. These savings would be driven by lower drug acquisition, drug administration and other health care resource use costs, including hospital and specialist visits. One-way sensitivity analysis confirmed base case results and identified current and future market shares for efgartigimod and rozanolixizumab as key parameters with an impact on the analysis.
CONCLUSIONS: The reimbursement of rozanolixizumab for gMG in Greece is projected to result in measurable savings on the third-party payer’s budget for gMG over five years. This positive budgetary impact, combined with rozanolixizumab’s mechanism of action, mode of administration and clinical benefits confirms rozanolixizumab as a valuable gMG treatment option in Greece.
METHODS: A budget impact model (BIM) was developed over a five-year time horizon (2025-2029) to estimate the cost of treating eligible gMG patients with existing therapies, including eculizumab, efgartigimod, ravulizumab, rituximab, intravenous immunoglobulin, or rozanolixizumab. Standard of care treatment is added to all comparators in clinical practice in Greece and was not accounted for in the BIM. The analysis incorporated epidemiological data on gMG prevalence and treatment uptake estimates. Patients received rozanolixizumab instead of eculizumab, efgartigomod, ravulizumab or rituximab. Rozanolixizumab had a mean annualized rate of 3.4 cycles and 17.8 infusions. Cost inputs included drug acquisition, administration, disease management and adverse event costs, sourced from market research, published literature and clinical expert input. Costs were presented in 2024 Euros.
RESULTS: Reimbursing rozanolixizumab for 2.9%, 3.1%, 3.7%, 4.5% and 5.2% of total eligible gMG patients in years 1 to 5 respectively would lead to a cumulative €10.9 million saving on the budget of EOPYY. These savings would be driven by lower drug acquisition, drug administration and other health care resource use costs, including hospital and specialist visits. One-way sensitivity analysis confirmed base case results and identified current and future market shares for efgartigimod and rozanolixizumab as key parameters with an impact on the analysis.
CONCLUSIONS: The reimbursement of rozanolixizumab for gMG in Greece is projected to result in measurable savings on the third-party payer’s budget for gMG over five years. This positive budgetary impact, combined with rozanolixizumab’s mechanism of action, mode of administration and clinical benefits confirms rozanolixizumab as a valuable gMG treatment option in Greece.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE94
Topic
Economic Evaluation, Health Technology Assessment
Topic Subcategory
Budget Impact Analysis
Disease
Neurological Disorders